Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972


Spotlight on Scrip Perspectives 24/25





Focus On Asia


Data Analysis


R&D


The Tourette’s Deal That Came Too Late To Save Sweden’s Asarina

 
• By 

Relmada has acquired sepranolone, a potential blockbuster for the complex neurological condition characterized by involuntary tics, for a bargain €3m from the Stockholm group that went into liquidation late last year.

10 Clinical Trials To Look Out For In 2025

 

Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.

AstraZeneca’s $80bn Ambition Riding On This Year’s Phase III Readouts

 

The company needs a string of Phase III wins this year to keep on track to reach $80bn revenues in 2030, with analysts still skeptical. Meanwhile, investors were relieved to learn that any fine related to a China corruption probe would be relatively modest.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

 

A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.

Business


Sionna IPO Grosses $191m To Compete With Vertex In CF

 
• By 

Sionna essentially doubled its cash on hand with its initial public offering to go up against a formidable competitor in cystic fibrosis with novel medicines applicable to a broad population.

Alumis To Merge With Acelyrin, But Pause Lonigutamab Program

 

Alumis said it will pause the planned Phase III program for Acelyrin’s lead drug and assess the value of the candidate, which produced underwhelming Phase II results in January.

The Tourette’s Deal That Came Too Late To Save Sweden’s Asarina

 
• By 

Relmada has acquired sepranolone, a potential blockbuster for the complex neurological condition characterized by involuntary tics, for a bargain €3m from the Stockholm group that went into liquidation late last year.

Bain To Acquire Mitsubishi Tanabe In $3.4bn Deal

 

US private equity group to buy Japanese pharma firm in a transaction scheduled to close by September that marks owner's exit from pharma.

Scrip Originals


Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease

 

Plus deals involving Vanda/AnaptysBio, OS Therapies/Ayala, Leveragen/Moonlight Bio, Lantheus/Evergreen, Exicure/GPCR, Arrivent/Lepu, InnoCare/KeyMed/Prolium and more.

Stock Watch: Why Investors Reacted Differently To Roche And J&J Q4 Updates

 
• By 

What a company says – and does not say – about its outlook can sway sentiment. Meanwhile, the snapshot of a big pharma’s quarterly results offers an insight to the circle of a portfolio’s life, with new products ascending to blockbuster status as previous blockbusters disappear.

Executives On The Move: Two CFOs And CCOs Each And Three CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Shanghai Bao Pharmaceutical and Alumis, plus Nurix Therapeutics acquires chief commercial officer from Arvinas.

Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three

 
• By 

Public Company Edition: A three-per-month IPO pace would top the 25 first-time biopharma offerings in 2024. Also, Akero grossed $402.5m and 89bio raised $250m in follow-on offerings that cashed in on Akero’s Phase IIb MASH readout. Immunovant raised $450m in a private placement.